Establishes joint venture with Wuxi municipal government; Expects the commercialization and revenues of HCCscreen<\/i>TM<\/sup> to accelerate in China<\/i><\/p>\n Project facilitates real-world data generation, representing an important step for early screening development and broader commercialization path<\/i><\/p>\n BEIJING–(BUSINESS WIRE<\/a>)– \nLed by the Wuxi municipal government (\u201cWuxi\u201d) and administered by the National Cancer Center (NCC) in China, the \u201cLiver Cancer Early Screening Comprehensive Prevention and Control Project\u201d is a public health initiative (the \u201cProject\u201d). The goal of the Project is to increase the awareness of liver cancer early screening, and to become a pilot city model in China. For the Project, Wuxi has selected HCCscreenTM<\/sup> for local residents who are high-risk individuals for HCC, and is committed to administering 150,000 tests over a period of three years. Wuxi had entered into a small-scale collaboration agreement with Genetron Health in 2019, and the Project represents an expanded collaboration between the parties. Wuxi is a city in the southern part of Jiangsu Province in eastern China with a population of over six million people, and has emerged as a biopharma innovation hub in recent years.\n<\/p>\n \nSeparately, Genetron Health has formed a new operating center through a joint venture agreement with Wuxi, in which the parties will closely collaborate on advancing the liver cancer early screening market in China, through the adoption of HCCscreenTM<\/sup>. Under this joint venture agreement, both parties will contribute capital, and Genetron Health will own 90% of the joint venture. In addition to the commitment of using HCCscreenTM<\/sup> for its residents, Wuxi will also provide Genetron Health with other supportive measures including rental, R&D subsidies and tax benefits.\n<\/p>\n \n\u201cWe are thrilled about this strategic partnership with Wuxi. It represents a major milestone for HCCscreenTM <\/sup>as it will be broadly used in a real-world setting, reflecting its clinical value that both the NCC and Wuxi recognized. Wuxi\u2019s investment and other supportive measures also highlight its commitment to advancing the liver cancer early screening in China,\u201d commented Sizhen Wang, Genetron Health\u2019s co-founder and CEO. \u201cThis partnership provides Genetron Health with near term revenue opportunities, as well as a cost-effective structure to build another world-class lab, manufacturing facility and an operating center for future developments. Beyond the financial benefits, the strategic value from this partnership is tremendous. It enables large-scale, real-world adoption of HCCscreenTM<\/sup>, representing an important step for our early screening product development, as well as potentially serving as a pilot model as we navigate the broader commercialization and reimbursement roadmaps in the future. Overall, we expect this initiative to ultimately help drive faster adoption of early cancer detection products in China.\u201d\n<\/p>\n About HCCscreenTM <\/sup>and Liver Cancer<\/b><\/p>\n \nIn September 2020, Genetron Health received the U.S. Food and Drug Administration (\u201cFDA\u201d)\u2019s Breakthrough Device designation for HCCscreenTM<\/sup>, and the product has been commercialized recently as a lab developed test (\u201cLDT\u201d) in China.\n<\/p>\n \nGlobally, liver cancer is the fourth most common cause of cancer-related death and the sixth in terms of incidence1<\/sup>. China represents the largest market, accounting for almost half of the global incidences. New incidence in China was estimated to be around 393,000 per year, with 369,000 deaths2<\/sup>. Market data by Frost and Sullivan estimated that as of 2019, among the 120 million high risk liver cancer population in China, around 74 million were HBV carriers.\n<\/p>\n \nPowered by Genetron Health\u2019s innovative and proprietary Mutation CapsuleTM<\/sup> technology, which enables detection of multiple methylation alterations in parallel with mutations in cell-free DNA from peripheral blood specimens, HCCscreenTM<\/sup> is currently being tested in its ongoing prospective study with 4,500 HBsAg+ individuals in HCC. As of the date of this announcement, 2,000 patients have already completed the study, and preliminary data from 297 patients at one center has demonstrated over 92% sensitivity, 93% specificity, compared to 67% and 99%, respectively in the ultrasound plus alpha-fetoprotein (AFP) arm. HCCscreenTM<\/sup> also achieved a 35% positive predictive value and 99.6% negative predictive value. Furthermore, stratifying by tumor sizes, of the 12 patients identified with HCC in the preliminary dataset, 10 patients had tumor sizes of less than 5 centimeters. Of these, seven patients had tumor sizes of less than 3 centimeters, and HCCscreen\u2122 successfully detected them all, indicating its ability in detecting early-stage HCC.\n<\/p>\n \nIn August 2020, Genetron Health announced its participation in the launch of a major national research project for early screening of lung and digestive system cancers led by China\u2019s Ministry of Science and Technology. The project is designed to include a multi-center, prospective cohort study in lung cancer of 120,000 high-risk individuals in 20 provinces, as well as a cohort study in digestive system cancer of more than 100,000 patients in urban areas in China. Genetron Health is the only company in China involved in national key research and development projects for liver, lung and digestive cancer early screening.\n<\/p>\n \nReferences:\n<\/p>\n About Genetron Holdings Limited<\/b><\/p>\n \nGenetron Holdings Limited (\u201cGenetron Health\u201d or the \u201cCompany\u201d) (Nasdaq:GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com.\n<\/p>\n Safe Harbor Statement<\/b><\/p>\n \nThis press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the prospects of the joint venture arrangement and plans for commercialization and expectation of revenues of HCCscreenTM<\/sup>, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are made under the \u201csafe harbor\u201d provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company\u2019s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as \u201cmay\u201d, \u201cwill,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cestimate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201cis\/are likely to\u201d or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company\u2019s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.\n<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20201127005238\/en\/<\/a><\/span><\/p>\n Investor Relations Contacts \nStephanie Carrington \nAsia: Media Relations Contact \nEdmond Lococo KEYWORDS:<\/b> China United States North America Asia Pacific<\/p>\n INDUSTRY KEYWORDS:<\/b> Biotechnology Medical Devices Health Genetics Oncology<\/p>\n MEDIA:<\/b><\/p>\n Genetron Health Provides Update on HCCscreen\u2122for Liver Cancer Early Screening in China HCCscreenTM was selected by the National Cancer Center and the Wuxi municipal government for use in the \u201cLiver Cancer Early Screening Comprehensive Prevention and Control Project\u201d, a public health initiative Establishes joint venture with Wuxi municipal government; Expects the commercialization and revenues of HCCscreenTM to accelerate in China Project facilitates real-world data generation, representing an important step for early screening development and broader commercialization path BEIJING–(BUSINESS WIRE)– Genetron Holdings Limited (\u201cGenetron Health\u201d or the \u201cCompany\u201d, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today provided an update for HCCscreenTM, its blood-based … <\/p>\n
\nGenetron Holdings Limited (\u201cGenetron Health\u201d or the \u201cCompany\u201d, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today provided an update for HCCscreenTM<\/sup>, its blood-based early screening test for hepatocellular carcinoma (\u201cHCC\u201d), in China.\n<\/p>\n\n
<\/p>\n
\n<\/b>
US:
\n
Hoki Luk
\n
Head of Investor Relations
\n
Email: hoki.luk@genetronhealth.com
\n<\/a>
Phone: +1 (408) 891-9255\n<\/p>\n
\n
Westwicke, an ICR Company
\n
Email: Stephanie.Carrington@westwicke.com
\n<\/a>
Phone: +1 (646) 277-1282\n<\/p>\n
\n
Bill Zima
\n
ICR, Inc.
\n
Email: bill.zima@icrinc.com
\n<\/a>
GenetronIR@icrinc.com<\/a><\/p>\n
\n<\/b>
Yanrong Zhao
\n
Genetron Health
\n
yanrong.zhao@genetronhealth.com<\/a><\/p>\n
\n
ICR
\n
Edmond.Lococo@icrinc.com
\n<\/a>
Mobile: +86 138-1079-1408
\n
genetron.pr@icrinc.com<\/a><\/p>\n\n","protected":false},"excerpt":{"rendered":"